Roche Products’ Alectinib
has been listed by the TGA as an
orphan drug for the treatment of
patients with anaplastic lymphoma
kinase (ALK)-positive non-small cell
lung cancer.
Lonoctocog Alfa from CSL Behring
Australia has also been listed as
a powder for reconstitution and
injection for the treatment in adults
and children with haemophilia A
(congenital FVIII deficiency).
The third recent addition
to the list of orphan drugs is
Tremelimumab by AstraZeneca as a
solution for infusion for treatment
of malignant mesothelioma.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.